Author

Kay Shigemori

Dana-Farber Cancer InstituteORCID 0000-0002-9682-4164Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Alan DenAdeliD· 1 shared Alejandro J. Gupta· 1 shared Alex K. ShalekiD· 1 shared Alexandria Van ScoykiD· 1 shared Andrew W. NaviaiD· 1 shared Ava P. AminiiD· 1 shared Catharine S. Leahy· 1 shared Charles CouturieriD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alan DenAdelORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Mutation and cell state compatibility is required and targetable in Ph+ acute lymphoblastic leukemia minimal residual disease

Peter S. Winter, Michelle L. Ramseier, Andrew W. Navia, Sachit D. Saksena, Haley Strouf, Nezha Senhaji, Alan DenAdel, Mahnoor Mirza, Hyun Hwan An, Laura L. Bilal, Peter S. Dennis, Catharine S. Leahy, Kay Shigemori, Jennyfer Galvez-Reyes, Ye Zhang, , Mark Alan Murakami

This study identifies mutation and transcriptional state compatibility in Ph+ ALL MRD, showing that targeting these interactions can overcome BCR::ABL1 independence and improve MRD monitoring.

bioRxiv · Jun 6, 2024 · PreprintCancer Biology